The researchers removed immune cells from the recipient’s blood and then disabled a gene in them using CRISPR–Cas9, which combines a DNA-cutting enzyme with a molecular guide that can be programmed to tell the enzyme precisely where to cut. A research team at Sichuan University in Chengdu have delivered modified cells to a patient with severe lung cancer via the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) – Cas9 technique as part of a clinical trial. The researchers say that they are hopeful that their findings will lead to new treatments for patients suffering from this disease. However, Naiyer Rizvi of Columbia University Medical Center in New York City doubts the trial will succeed.
A research team at Sichuan University in Chengdu have delivered modified cells to a patient with severe lung cancer via the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) – Cas9 technique as part of a clinical trial. The researchers say that they are hopeful that their findings will lead to new treatments for patients suffering from this disease. However, Naiyer Rizvi of Columbia University Medical Center in New York City doubts the trial will succeed.